Pardes Biosciences Inc

NASDAQ:PRDS  
3.42
-0.90 (-20.83%)
Products

Pardes Biosciences Says FDA Granted Fast Track Designation For PBI-0451

Published: 06/09/2022 10:17 GMT
Pardes Biosciences Inc (PRDS) - Pardes Biosciences Inc - on June 6, FDA Granted Fast Track Designation for Pbi-0451.
Pardes Biosciences - Sees Enrolling Global, Placebo-controlled Phase 2 Clinical Trial in Vaccinated/unvaccinated Participants With Mild-to-moderate Covid-19 Later This Year.
Pardes Biosciences - Anticipates Generating Data From Phase 3 Registrational Trials in 2023.